Citations

Clear

1526 citation(s) found for "Sun, C".

Reversal of nonalcoholic fatty liver disease reduces the risk of cardiovascular disease among Korean
Jeong, Seogsong , Park, Sun Jae , Ahn, Joseph , Park, Sang Min , Park, Sang Min , Ahn, Joseph C , Oh, Yun Hwan

Mayo Clinic

Medicine | November 28, 2023 | Volume: 102 | Issue: 44 | Pages: e35804

10.1097/md.0000000000035804 | PMID 37933021 Get It

Nonalcoholic fatty liver disease (NAFLD) is considered an independent risk factor for the development of cardiovascular disease. However, the association between changes in NAFLD status and the risk of cardiovascular disease (CVD) remains uncertain. Starting January 1, 2013, participants were followed until the occurrence of CVD event, death, or December 31, 2020. This was a population-based cohort study that included data from adults aged ≥ 20, who underwent 2 consecutive health screenings from 2009 to 2012. NAFLD was defined as a Fatty Liver Index ≥ 60 at each screening. The primary endpoint was a CVD event, which encompassed ischemic heart disease and cerebrovascular disease. The association between changes in NAFLD status and the risk of CVD was determined using multivariable Cox proportional hazards regression. This cohort comprised 4656,305 adults with a median age of 53 years. During 36,396,968 person-years of follow-up, 238,933 (5.1%) CVD events were observed. Compared to patients with no NAFLD at both screenings, patients who developed NAFLD at the second screening exhibited an increased risk of CVD (adjusted hazard ratio, 1.15; 95% confidence interval, 1.13–1.17). In contrast, individuals who recovered from NAFLD at the second screening demonstrated a reduced CVD risk compared to those with persistent NAFLD (adjusted hazard ratio, 0.91; 95% confidence interval, 0.90–0.92). The reversal of NAFLD is associated with a reduced risk of CVD. Therefore, focusing on NAFLD treatment could serve as a clinical target for lowering CVD risk.
Proximal immune-epithelial progenitor interactions drive chronic tissue sequelae post COVID-19
Sun, Jie , Narasimhan, Harish , Cheon, In Su , Qian, Wei , Li, Chaofan , Goplen, N. , Wu, Yue , Wei, Xiaoqin , Son, Young Min , Yao, Changfu , Canderan, Glenda , Kadl, Alexandra , Cannon, Abigail R. , Young, Samuel , Hannan, Riley, Bingham, Grace C. , Chaudhari, Arka Sen, Pramoonjago, Patcharin , Woodfolk, Judith A. , Li, Chaofan , Goplen, Nicholas P , Wu, Y , Yao, Changfu , Zang, Chongzhi , Sun, Jie , Hu, Shengen Shawn , Parimon, Tanyalak , Fink, Elizabeth , Santos, Gislane de Almeida , Tang, Jinyi , Muehling, Lyndsey M. , Cannon, Abigail, Arish, Mohammad, Sturek, Jeffrey M , Shim, Yun M. , Chen, Peter

Mayo Clinic

No container title available | November 28, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3587418/v1 | PMID 38077031 Get It

Abstract The long-term physiological consequences of SARS-CoV-2, termed Post-Acute Sequelae of COVID-19 (PASC), are rapidly evolving into a major public health concern. The underlying cellular and molecular etiology remain poorly defined but growing evidence links PASC to abnormal immune responses and/or poor organ recovery post-infection. Yet, the precise mechanisms driving non-resolving inflammation and impaired tissue repair in the context of PASC remain unclear. With insights from three independent clinical cohorts of PASC patients with abnormal lung function and/or viral infection-mediated pulmonary fibrosis, we established a clinically relevant mouse model of post-viral lung sequelae to investigate the pathophysiology of respiratory PASC. By employing a combination of spatial transcriptomics and imaging, we identified dysregulated proximal interactions between immune cells and epithelial progenitors unique to the fibroproliferation in respiratory PASC but not acute COVID-19 or idiopathic pulmonary fibrosis (IPF). Specifically, we found a central role for lung-resident CD8+ T cell macrophage interactions in maintaining Krt8hi transitional and ectopic Krt5+ basal cell progenitors, thus impairing alveolar regeneration and driving fibrotic sequelae after acute viral pneumonia. Mechanistically, CD8+ T cell derived IFN-γ and TNF stimulated lung macrophages to chronically release IL-1β, resulting in the abnormal accumulation of dysplastic epithelial progenitors and fibrosis. Notably, therapeutic neutralization of IFN-γ and TNF, or IL-1β after the resolution of acute infection resulted in markedly improved alveolar regeneration and restoration of pulmonary function. Together, our findings implicate a dysregulated immune-epithelial progenitor niche in driving respiratory PASC. Moreover, in contrast to other approaches requiring early intervention, we highlight therapeutic strategies to rescue fibrotic disease in the aftermath of respiratory viral infections, addressing the current unmet need in the clinical management of PASC and post-viral disease.
To what extent are first‐year medical students willing to disclose errors: relating a reflective writing exercise in gross anatomy to medical error disclosure
Wittich, Christopher M. , Lachman, Nirusha , Pawlina, Wojciech, Sun, Philip Y.

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.787.11 Get It

Medical error is an important cause of patient morbidity/mortality. Disclosing medical errors to patients is an important component of safe practice. There is a growing need to assess the inherent nature of how physicians in training approach such unanticipated outcomes. With limited exposure for medical students to the idea of medical error disclosure, which is an important area of professionalism in medicine, we believe that a reflective writing exercise can be an efficient tool to objectively assess how students acknowledge and address medical errors early in their medical career. Every year, students in the 1 st year gross anatomy course are asked to respond to a scenario in which a medical student's cellular phone conversation with a friend in a public area (i.e. post office) was overheard by a family member of a cadaver donor to Mayo Medical School. Students were asked to write an apology email to the offended party (Mrs. X) as though they were the student who made the mistake. Students were given 48 hours to complete and submit the assignment. We retrospectively reviewed the medical error disclosure assignment of medical students in the first‐year gross anatomy course at Mayo Medical School between 2005 and 2015. An instrument for assessing medical error disclosure, consisting of fifteen items evaluated on Likert scale (1–5, 1 is the lowest and 5 is the highest), was developed. Using this evaluation tool, we assessed the basic elements of medical error disclosure – acknowledgement of error/system failure, expression of regret, awareness of its impact, description of future behavior, and proper tone as an apology letter. Preliminary data from years 2005, 2008, 2011, and 2014 indicated the mean error disclosure scores of 3.49 ± 0.83, 3.32 ± 0.81, 3.29 ± 0.84, and 3.25 ± 0.75, respectively. The word count in those four class years were 246.9 ± 84.0, 236.3 ± 86.4, 211.2 ± 92.3, and 242.3 ± 79.1 words, respectively. The proportion of students who claimed to have spoken with his/her mother was 2 out of 42 (4.7%), 4 out of 49 (8.2%), 0 out of 48 (0%), and 20 out of 51 (39%) students, respectively. Across the four class years, there was a non‐significant but uniform trend of reduced mean error disclosure score over time, while the mean word count did not show a certain pattern. One notable trend over the class years was an increasing attribution to their mother as the person they spoke with, possibly a way to help alleviate Mrs. X's frustration by eliciting empathy. Overall, this efficient, integrated writing exercise serves as a sensitive tool to objectively gauge skills in the basic areas of medical error disclosure in a preclinical anatomy course. Support or Funding Information My sponsor is Dr. Wojciech Pawlina, the senior author of the abstract. Funding will be considered by the Department of Anatomy, Mayo Clinic College of Medicine, Rochester, MN.
Adenosine A2A Receptor Driven Impulsivity Promotes Cue‐Dependent Reward Seeking Behavior and Increases Hippocampal Immature Neurons
Oliveros, Alfredo , Cho, Chang Hoon , Choi, Sun, Jang, Mi‐Hyeon , Choi, Doo‐Sup

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.704.8 Get It

Mice lacking the ethanol‐sensitive equilibrative nucleoside adenosine transporter 1 (ENT1 –/– ) display enhanced goal‐directed behaviors due to decreased adenosine A 2A R function. However, the role of A 2A R signaling in the regulation of impulsivity remains unknown. Using Pavlovian conditioning, second‐order schedule discrimination, and the 5‐choice serial reaction time task (5‐CSRTT), which incorporates differential‐reward of low rate (DRL) schedules, we reveal that deficits in A 2A R function promote impulsivity. ENT1 –/– mice display exaggerated impulsive responses and faster reaction times to retrieve reward during conditioning and extinction. Interestingly, our results show that basal ERK1/2 phosphorylation is reduced in the dorsal hippocampus (dHPC) of ENT1 –/– mice and that impulsive Pavlovian conditioning significantly increases ERK1/2 phosphorylation. Subsequently, we validate that inhibition of A 2A R promotes impulsivity during Pavlovian conditioning and the 5‐CSRTT. In addition to increased ERK1/2 phosphorylation, mice demonstrating exaggerated impulsivity as a result of A 2A R inhibition exhibit enhanced expression of doublecortin and increased incorporation of BrdU within the HPC. Taken together, these findings indicate that impaired ENT1/A 2A R signaling promotes impulsivity during cue‐induced conditioning and contributes to reward seeking during extinction. More importantly, these results demonstrate that impulsive behavior is associated with aberrant hippocampal neurogenesis, which may contribute to the development of maladaptive reward‐seeking behaviors. Support or Funding Information NIH R01 AA018779
EPCO-22. LONGITUDINAL MOLECULAR CHARACTERIZATION IDENTIFIES TREATMENT DRIVEN EVOLUTION OF OLIGODENDROGLIOMA
Heo, Chaewon, Ghospurkar, Padmaja L. , Wade, Taylor , Costello, J , Elliott, Carol, Hermes, Beth, Hong, Chibo, Li, Kay Ka‐Wai , Lowman, Allison , McCortney, Katy, Moon, Hyo-Eun, Paek, Sun Ha , Westcott, Kerryn T., Verhaak, Roel G.W. , Chowdhury, Tamrin , Johnson, Kevin C. , Kocakavuk, Emre , Ye, Gordon Y. , Barnholtz‐Sloan, Jill S. , French, Pim J. , Golebiewska, Anna , Horbinski, Craig , Khasraw, Mustafa , LaViolette, Peter S , Lipp, Eric , McCortney, Katy, Ng, Ho‐Keung , Padovan, Marta , Vallentgoed, Wies , Vaubel, Rachael A. , Wesseling, Pieter , Varn, Frederick S.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v128-v128

10.1093/neuonc/noad179.0485 Get It

Abstract Oligodendroglioma is characterized by oligodendrocyte-like histology, mutation in the IDH genes, along with codeletion of chromosome arms 1p and 19q. Treatment for oligodendrogliomas combines surgery, followed by observation, and chemotherapy and/or radiotherapy when tumors progress. Most oligodendrogliomas eventually recur with a more aggressive phenotype, leading to patient mortality but molecular mechanisms remain poorly understood. To investigate the molecular trajectory of oligodendroglioma, we collected more than 270 longitudinal samples from over 130 oligodendroglioma patients, to perform whole genome or whole exome sequencing, bulk RNA, and single-nucleus RNA sequencing (n = 30 samples). Common mutations in IDH1/2, TERT promoter, CIC, and FUBP1 were observed. About half of the CIC and FUBP1 mutations occurred in the initial sample and persisted stably throughout recurrence. The majority of PIK3CA and PIK3R1 mutations were either shared or present in recurrences only implicating the PI3K pathway in oligodendroglioma recurrence. Mutational signature analysis revealed 34.5% of tumors treated with alkylating agents acquired SBS11/SBS31 associated hypermutation. By integrating signatures with clonality estimates, we approximated the timing of mutational processes and found that clonal timings of treatment related mutations correlate with the treatment administration date. We found that aging signature-related mutations were mostly clonal, and treatment signature-related mutations were more likely to be sub-clonal, supporting the late emergence of these mutations following treatment. We observed increased somatic copy number alterations in oligodendroglioma recurrences, reflected in notable chromosome 4 losses. Associating treatment with snRNAseq derived cellular states, we observed a significant increase in the fraction of proliferating stem-like cells in the hypermutator versus non-hypermutator recurrent samples. These findings shed light on the molecular changes occurring in oligodendrogliomas following treatment and provide insights that may aid in targeting treatment resistance.
Author response: Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
Vinayak, Shaveta , Sun, Tianyi , Kuderer, Nicole M. , Balmaceda, Nicole , Bilen, Mehmet Asım , Bindal, Poorva , Blau, Sibel , Bodin, Brianne E, Borno, Hala T. , Choi, Horyun, Deeken, John F. , Edwin, Natasha, Feldman, Lawrence , Flora, Daniel , Galsky, Matthew D. , Gonzalez, Cyndi J, Grivas, Petros , Gupta, Shilpa , Haynam, Marcy , Heilman, Hannah, Jhawar, Sachin R, Kaklamani, Virginia , Klein, Elizabeth J. , Koshkin, Vadim S. , Kulkarni, Amit , Kwon, Daniel H. , Lammers, Philip E. , Lathrop, Kate, Lewis, Mark A. , Lopes, Gilbert de Lima, Makower, Della , Mansoor, Abdul-Hai, Mashru, Sandeep H., McKay, Rana R. , Messing, Ian , Mico, Vasil, Nadkarni, Rajani, Namburi, Swathi, Nguyen, Ryan H, Nonato, Taylor K., Park, Kyu, Patel, Jaymin , Patel, Kanishka G. , Peppercorn, Jeffrey , Polimera, Hyma , Puc, Matthew , Reid, Sonya , Riess, Jonathan W. , Rivera, Donna R. , Russ, Atlantis Dawn, Schapira, Lidia , Shanahan, M Kelly, Smits, Melissa, Streckfuss, Mitrianna, Thompson, Michael A, Tolaney, Sara M. , Weissmann, Lisa B., Wilson, Grace, Wulff‐Burchfield, Elizabeth , French, Benjamin , Accordino, Melissa , Nagaraj, Gayathri , Khaki, Ali Raza , Aboulafia, David M. , Acoba, Jared David , Awosika, Joy A. , Bakouny, Ziad , Bao, Ting , Bashir, Babar , Berg, Stephanie , Castellano, Cecilia A. , Desai, Aakash , Friese, Christopher R. , Hershman, Dawn L. , Hwang, Clara , Jani, Chinmay , Jhawar, Sachin R, Joshi, Monika , Knox, Natalie, Labaki, Chris , Li, Xuanyi , Lyman, Gary H , Markham, Merry Jennifer , Nguyen, Ryan H, O’Connor, Tracey L. , Panagiotou, Orestis A. , Rao, Yuan James , Razavi, Pedram , Robson, Mark E. , Rose, Suzanne J. , Shah, Pankil , Shapiro, Lauren C. , Stover, Daniel G. , Tachiki, Lisa , Thompson, Michael A, Wotman, Michael T. , Mishra, Sanjay , Warner, Jeremy L. , Lustberg, Maryam B. , Shah, Dimpy P.

Mayo Clinic

No container title available | November 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.82618.sa2 Get It

729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors
Lee, Jeeyun , Campian, Jian , Zhao, Yujie , Seetharam, ­Mahesh , Adjei, Alex A. , Yun, Nari, Lee, Woo-Sun, Lee, Wooyul, Park, Sosun, Seo, Bochan, Lee, Kyungwha, Park, Chong Woo, Cho, Byoung Chul , Lee, Jae‐Lyun , Lee, Jung-Yun , Wee, Wen , Chae, Dongwoo , Jang, Myoung Ho

Mayo Clinic

Regular and Young Investigator Award Abstracts | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: A824-A824

10.1136/jitc-2023-sitc2023.0729 Get It

First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
Scherpereel, Arnaud , Antonia, Scott , Bautista, Y., Zalcman, Gérard , Sun, Xuezheng , Padilla, Brad , Aanur, Praveen , Daumont, M. , Bennett, Bryan , McKenna, M., Baas, P, Zalcman, Gérard , Bischoff, Hervé , Grossi, Francesco , Kowalski, Dariusz M. , Nowak, Anna K. , Fujimoto, Nobukazu , Peters, Solange , Tsao, Anne S. , Mansfield, Aaron S. , Popat, Sanjay , Bennett, B, Baas, P

Mayo Clinic

Pneumologie | October 26, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0041-1723293 Get It

Ein globaler Consensus zu Definitionen, Diagnostik und Behandlungsmanagement des fibrostenotischen Morbus Crohn des terminalen Ileums
Baker, Mark E. , Bemelman, Willem A. , D’Haens, Geert , D’Hoore, A., Feakins, Roger , Fleshner, Phillip , Ha, Christina , Lyu, R., Mao, Ren , Sandborn, William J. , Ng, S, Silverberg, Mark S. , Bruining, David H. , Feagan, Brian G. , Bettenworth, Dominik , Fletcher, Joel G. , Jairath, Vipul , Lu, Cathy , Dignass, Axel , Dotan, Iris , Henderson, G., Panés, Julián , Rogler, Gerhard , Rimola, Jordi , Siegmund, Britta , Taylor, Stuart A. , Verstockt, Bram , Gordon, Ilyssa O. , Rieder, F.

Mayo Clinic

Zeitschrift für Gastroenterologie | October 26, 2023 | Volume: 61 | Issue: 08 | Pages: e421-e422

10.1055/s-0043-1771750 Get It

Identifying metabolic features of colorectal cancer liability using Mendelian randomization
Bull, Caroline J. , Hazelwood, Emma , Tan, Vanessa Y. , Constantinescu, Andrei‐Emil , Borges, Maria Carolina , Legge, Danny , Burrows, Kimberley , Huyghe, Jeroen R. , Li, Li , Pai, Rish K. , Figueiredo, Jane C. , Borges, Maria C , Bull, Caroline J , Legge, Danny , Hazelwood, Emma , Bell, Joshua A. , Brenner, Hermann , Castellvı́-Bel, Sergi , Chan, Andrew T. , Kweon, Sun-Seog , Marchand, Loı̈c Le , Cheng, Iona C. , Murphy, Neil , Gunter, Marc J. , Timpson, Nicholas J. , Vincent, Emma E.

Mayo Clinic

No container title available | October 17, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.87894.2 Get It

Recognizing the early signs of cancer risk is vital for informing prevention, early detection, and survival. To investigate whether changes in circulating metabolites characterise the early stages of colorectal cancer (CRC) development, we examined associations between a genetic risk score (GRS) associated with CRC liability (72 single nucleotide polymorphisms) and 231 circulating metabolites measured by nuclear magnetic resonance spectroscopy in the Avon Longitudinal Study of Parents and Children (N=6,221). Linear regression models were applied to examine associations between genetic liability to colorectal cancer and circulating metabolites measured in the same individuals at age 8, 16, 18 and 25 years. The GRS for CRC was associated with up to 28% of the circulating metabolites at FDR-P<0.05 across all time points, particularly with higher fatty acids and very-low- and low-density lipoprotein subclass lipids. Two-sample reverse Mendelian randomization (MR) analyses investigating CRC liability (52,775 cases, 45,940 controls) and metabolites measured in a random subset of UK Biobank participants (N=118,466, median age 58y) revealed broadly consistent effect estimates with the GRS analysis. In conventional (forward) MR analyses, genetically predicted polyunsaturated fatty acid concentrations were most strongly associated with higher CRC risk. These analyses suggest that higher genetic liability to CRC can cause early alterations in systemic metabolism, and suggest that fatty acids may play an important role in CRC development.